. Author manuscript; available in PMC: 2022 Jul 1.

Published in final edited form as: Cytometry B Clin Cytom. 2020 Oct 5;100(4):497–508. doi: 10.1002/cyto.b.21961

Table 5.

Comparison of gating strategies used for detecting plasma cells after treatment with daratumumab and elotuzumab

Gating parameters^a	Fold change (SD)^b
Gating parameters^a	Untreated	10 μg/mL daratumumab	100 μg/mL elotuzumab	10 μg/mL daratumumab & 100 μg/mL elotuzumab
A. Approach 1
CD38, CD138, CD45	1.00 (0)^b	0 (0)	1.06 (0.09)	0 (0)
p-value	-	< 0.001	NS	< 0.001
B. Approach 2
CD319, CD138, CD45	1.00 (0.11)	1.01 (0.07)	1.05 (0.09)	0.75 (0.24)
p-value	NS	NS	NS	NS
C. Approach 3
CD38/CD319, CD138, CD45	1.03 (0.12)	0.96 (0.03)	1.00 (0.04)	0.79 (0.33)
p-value	NS	0.086	NS	NS

All cells were pre-gated using Time vs. FSC-A, FSC-A vs. FSC-H, and FSC-A vs. SSC-A to identify hematopoietic cells that are valid, singlet, and viable.

Untreated plasma cells characterized by CD38br, CD138+, CD45lo was considered as the reference population; all analyses were normalized to this population.

NS: not significant.